Extended peginterferon plus ribavirin treatment for 72 weeks versus standard peginterferon plus ribavirin treatment for 48 weeks in chronic hepatitis C genotype 1 infected slow-responder adult patients: Cochrane systematic review
Extended peginterferon plus ribavirin treatment for 72 weeks versus standard peginterferon plus ribavirin treatment for 48 weeks in chronic hepatitis C genotype 1 infected slow-responder adult patients: Cochrane systematic review is a topic covered in the Cochrane Abstracts.
To view the entire topic, please log in or purchase a subscription.
Evidence Central is an integrated web and mobile solution that helps clinicians quickly answer etiology, diagnosis, treatment, and prognosis questions using the latest evidence-based research. Explore these free sample topics:
There's more to see -- the rest of this topic is available only to subscribers.
Citation
"Extended Peginterferon Plus Ribavirin Treatment for 72 Weeks Versus Standard Peginterferon Plus Ribavirin Treatment for 48 Weeks in Chronic Hepatitis C Genotype 1 Infected Slow-responder Adult Patients: Cochrane Systematic Review." Cochrane Abstracts, Evidence Central, evidence.unboundmedicine.com/evidence/view/Cochrane/436184/all/Extended_peginterferon_plus_ribavirin_treatment_for_72_weeks_versus_standard_peginterferon_plus_ribavirin_treatment_for_48_weeks_in_chronic_hepatitis_C_genotype_1_infected_slow_responder_adult_patients:_Cochrane_systematic_review. Accessed 01 July 2022.
Extended peginterferon plus ribavirin treatment for 72 weeks versus standard peginterferon plus ribavirin treatment for 48 weeks in chronic hepatitis C genotype 1 infected slow-responder adult patients: Cochrane systematic review. Cochrane Abstracts. https://evidence.unboundmedicine.com/evidence/view/Cochrane/436184/all/Extended_peginterferon_plus_ribavirin_treatment_for_72_weeks_versus_standard_peginterferon_plus_ribavirin_treatment_for_48_weeks_in_chronic_hepatitis_C_genotype_1_infected_slow_responder_adult_patients:_Cochrane_systematic_review. Accessed July 1, 2022.
Extended peginterferon plus ribavirin treatment for 72 weeks versus standard peginterferon plus ribavirin treatment for 48 weeks in chronic hepatitis C genotype 1 infected slow-responder adult patients: Cochrane systematic review. In Cochrane Abstracts https://evidence.unboundmedicine.com/evidence/view/Cochrane/436184/all/Extended_peginterferon_plus_ribavirin_treatment_for_72_weeks_versus_standard_peginterferon_plus_ribavirin_treatment_for_48_weeks_in_chronic_hepatitis_C_genotype_1_infected_slow_responder_adult_patients:_Cochrane_systematic_review
Extended Peginterferon Plus Ribavirin Treatment for 72 Weeks Versus Standard Peginterferon Plus Ribavirin Treatment for 48 Weeks in Chronic Hepatitis C Genotype 1 Infected Slow-responder Adult Patients: Cochrane Systematic Review [Internet]. In: Cochrane Abstracts. [cited 2022 July 01]. Available from: https://evidence.unboundmedicine.com/evidence/view/Cochrane/436184/all/Extended_peginterferon_plus_ribavirin_treatment_for_72_weeks_versus_standard_peginterferon_plus_ribavirin_treatment_for_48_weeks_in_chronic_hepatitis_C_genotype_1_infected_slow_responder_adult_patients:_Cochrane_systematic_review.
* Article titles in AMA citation format should be in sentence-case
TY - ELEC
T1 - Extended peginterferon plus ribavirin treatment for 72 weeks versus standard peginterferon plus ribavirin treatment for 48 weeks in chronic hepatitis C genotype 1 infected slow-responder adult patients: Cochrane systematic review
ID - 436184
BT - Cochrane Abstracts
UR - https://evidence.unboundmedicine.com/evidence/view/Cochrane/436184/all/Extended_peginterferon_plus_ribavirin_treatment_for_72_weeks_versus_standard_peginterferon_plus_ribavirin_treatment_for_48_weeks_in_chronic_hepatitis_C_genotype_1_infected_slow_responder_adult_patients:_Cochrane_systematic_review
DB - Evidence Central
DP - Unbound Medicine
ER -